Analysis of:
Schering releases ENHANCE data today (www.tradingmarkets.com)
Merck and Schering Plough has finally released the ENHANCE trial. The results were bad- and the cover up was worse. Those who predict no fall out from this study are kidding themselves.
Analysis of:
Schering releases ENHANCE data today (www.tradingmarkets.com)
Physicians have several possible conclusions that can be taken; These include:
- the trial is flawed - the selection of patients with much less CIMT than previous trials such as ASAP and ARBITER flaws the study
- the failure to meet the trial endpoint is only a surrogate and clinical trial data...
Analysis of:
Amarin Commences First Clinical Trial in Cardiovascular Program (www.pipelinereview.com)
Niacin is the most potent approved HDL-raising agent with evidence for cardiovascular benefit. Flush is the limiting side-effect. EPA (a major component of omega 3 fish oil) decreases triglycerides and may have antiarrhythmic properties.
Analysis of:
AstraZeneca Files Patent Infringement Actions in Response to Crestor(TM) ANDAs (www.pipelinereview.com)
Challenges to pharmaceutical patents prior to the "official" expiration of the patent are proliferating; if they are allowed to stand, that is, if the "original" patent is successfully voided one of the crucial financial incentives to novel pharmaceutical research will be abridged and the "profit" motive...
Analysis of:
NATRECOR Authorized In Canada For Treatment Of Acute Decompensated Heart Failure (www.medicalnewstoday.com)
This is great news for Canada. This is the first new drug approved for the treatment of acute heart failure since 1989, when milrinone was approved. Nesiritide was approved in the United States in 2001. Since then, it has proven to be of great benefit in patients with acute heart failure,...
Analysis of:
Leavitt: Doctors Need Electronic Records (www.sfgate.com)
This is no real solution to the medicare problem. EMR and the medicare cuts are really separate issues. These type of mandates will make it almost impossible for small practices.
Analysis of:
Toshiba Introduces FaCTor64 Study To Improve Early Diagnosis And Treatment Of Coronary Artery Disease In Asymptomatic Diabetics (www.medicalnewstoday.com)
The CorE 64 is the latest in coronary imaging technologies, but it is unclear what the provided results mean and what doctors need to do about them. The results of the initial study presented at the American Heart Association Scientific Sessions sparked an intense debate about the role of coronary computed...
Analysis of:
Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events (pharmalive.com)
The meta-analysis of the rimonabant trials points to an increase in psychiatric diagnoses. What is missing in this report is the numberical and statistical significance of the findings. This debate needs more rigor; the type of rigor that is applied to cardiac endpoints, needs to be applied here. ...
Analysis of:
Pramlintide and Leptin Combination Treatment Demonstrates 12.7 Percent Weight Loss in 24-Week Clinical Obesity Study (www.pipelinereview.com)
No safety signal so far giving problems is obviously a good sign. Thsi magnitude of weight loss beats all other pharmacologic weight loss options so far.
Analysis of:
GlaxoSmithKline revises US labeling for Avandia (www.pipelinereview.com)
Most diabetics have subclinical CAD, and a baseline risk of CAD equivalent to that of a person without diabetes and a prior MI. This drug, by limiting its labelling is severely limiting its use in patients with diabetes.